alemtuzumab (Campath)

• Alemtuzumab is an injectable drug used for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). People with CLL have too many of a type of white blood cell called lymphocytes in the blood and bone marrow. Alemtuzumab is an antibody that targets a protein called CD52 that is found on the surface of the lymphocytes. Alemtuzumab attaches to lymphocytes and then activates the immune system to help kill the lymphocytes.
• The FDA approved alemtuzumab in May, 2001.

Is alemtuzumab available as a generic drug?

No

Do I need a prescription for alemtuzumab?

Yes

Alemtuzumab is used alone for the treatment of B-cell chronic lymphocytic leukemia (B-CLL)

Common side effects include:

• Low blood cell counts
• Infusion reactions
• Cytomegalovirus (CMV) and other infections
• Nausea
• Vomiting
• Diarrhea
• Insomnia
• Fever
• Chills

Other side effects include:

• Rash
• Itching
• Headache
• Tremor
• Anxiety
• Shortness of breath

• Alemtuzumab is given by intravenous infusion over 2 hours. The dose should be gradually increased to the recommended dose of 30 mg/day three times per week for 12 weeks.
• Medications that should be given during alemtuzumab therapy to prevent side effects and infections include oral antihistamines, acetaminophen (Tylenol), trimethoprim/sulfamethoxazole DS (Bactrim DS), and famciclovir (Famvir).

Alemtuzumab drug interaction studies have not been conducted.

• Proteins such as alemtuzumab, may cross the placental barrier and may be excreted in breast milk. Alemtuzumab has not been studied in pregnant women or nursing mothers. It should be given to a pregnant or nursing woman only if clearly needed.

What preparations of alemtuzumab are available?

Injection (single use vial): 30 mg/vial

How should I keep alemtuzumab stored?

Alemtuzumab should be stored at 2 C to 8 C (36 F to 46 F), protected from light, and not frozen. If frozen, thaw to 2 to 8 C before administration.